Market Overview

Dyax Announces Positive DX-2930 and Biomarker Assay Data at ASH


Dyax Corp. (NASDAQ: DYAX) today announced positive results from both preclinical studies of the investigational product DX-2930 and its biomarker assay program for detection of contact system activation of plasma kallikrein (pKal). Data were presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 7-10 in New Orleans, LA.#ASH13

See full press release

Posted-In: News Guidance Management Global


Related Articles (DYAX)

View Comments and Join the Discussion!